In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 805-813

  Rashidi, Mohammad R ^b   Smith, John A ^b   Clarke, Stephen E ^b   Beedham, Christine ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 DEOXYPENCICLOVIR; ALDEHYDE OXIDASE; FAMCICLOVIR;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG OXIDATION; ENZYME ACTIVITY; GUINEA PIG; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

2-AMINOPURINE; ACYCLOVIR; ALDEHYDE OXIDASE; ALDEHYDE OXIDOREDUCTASES; ANIMALS; ANTIVIRAL AGENTS; BIOTRANSFORMATION; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FEMALE; GUINEA PIGS; HUMANS; KINETICS; LIVER; MALE; OXIDATION-REDUCTION; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; XANTHINE OXIDASE;

ANIMALIA; BOVINAE; CAVIA PORCELLUS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0030840879     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. C. M. Perry and A. J. Wagstaff: Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 50, 396-415 (1995).
2. R. A. Vere Hodge and Y. -C. Cheng: The mode of action of penciclovir. Antiviral Chem. Chemother. 4(Suppl. 1), 13-24 (1993).
3. F. A. Alrabian and S. L. Sacks: New antiherpes virus agents. Drugs 52, 17-32 (1996).
4. M. A. Pue and L. Z. Benet: Pharmacokinetics of famciclovir in man. Antiviral Chem. Chemother. 4(Suppl. 1), 47-55 (1993).
5. A. B. Murray: Valaciclovir: an improvement over acyclovir for the treatment of zoster. Antiviral Chem. Chemother. 6, 34-38 (1995).
6. R. A. Vere Hodge, D. Sutton, M. R. Boyd, M. R. Harnden, and R. L. Jarvest: Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33, 1765-1773 (1989).
7. T. A. Krenitsky, W. W. Hall, P. de Miranda, L. M. Beauchamp, H. J. Schaeffer, and P. L. Whiteman: 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc. Natl. Acad. Sci. 81, 3209-3213 (1984).
8. A. W. Harrell, S. M. Wheeler, M. Pennick, S. E. Clarke, and R. J. Chenery: Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6β-hydroxylation of testosterone in human liver microsomes. Drug Metab. Dispos. 21, 18-23 (1993).
9. S. E. Clarke, A. W. Harrell, and R. J. Chenery: Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab. Dispos. 23, 251-254 (1995).
10. M. R. Rashidi: In vitro oxidation of purines by hepatic molybdenum hydroylases. Ph.D. Thesis, University of Bradford, UK (1996).
11. 1-methynicotinamide in man and rat. Arch. Biochem. Biophys. 145, 35-42 (1971).
12. T. A. Krenitsky, V. Tuttle, E. L. Cattau, and P. Wang: A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase. Comp. Biochem. Physiol. 49B, 687-703 (1974).
13. C. Beedham: Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. In "Progress in Medicinal Chemistry" (G. P. Ellis, and G. B. West, Eds.), Vol. 24, pp. 85-127, Elsevier, New York (1987).
14. C. Beedham, S. E. Bruce, D. J. P. Critchley, Y. Al-Tayib, and D. J. Rance: Species variation in hepatic aldehyde oxidase activity. Eur. J. Drug Metab. Pharmacokin. 12, 307-310 (1987).
15. C. Beedham, D. J. P. Critchley, and D. J. Rance: Substrate specificity of human liver aldehyde oxidase towards substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit and baboon. Arch. Biochem. Biophys. 319, 481-490 (1995).
16. D. B. Jones, V. K. Rustgi, D. M. Kornhauser, A. Woods, R. Quinn, J. H. Hoofnagle, and A. Jones: The disposition of 6-deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir in the isolated perfused rat liver. Hepatology 7, 345-348 (1987).
17. K. R. Iyer: Evaluation and metabolism of (-)-6-deoxycarbovir as a prodrug for (-)-carbovir. Dissertation Abst. Inter. 53, 1313-B (1992).
18. A. W. Harrell, S. M. Wheeler, P. East, S. E. Clarke, and R. J. Chenery: Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent. Drug Metab. Dispos. 22, 189-193 (1994).
19. C. Johnson, C. Stubley-Beedham, and J. G. P. Stell: Elevation of molybdenum hydroxylase levels in rabbit liver after ingestion of phthalazine or its hydroxylated metabolite. Biochem. Pharmacol. 33, 3699-3705 (1984).
20. C. Beedham, S. E. Bruce, D. J. Critchley, and D. J. Rance: 1-Substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases. Biochem. Pharmacol. 39, 1213-1221 (1990).
21. K. V. Rajagopalan, I. Fridovich, and P. Handler: Hepatic aldehyde oxidase: I. purification and properties. J. Biol. Chem. 237, 922-928 (1962).
22. G. A. C. Murrell and W. G. Rapeport: Clinical pharmacokinetics of allopurinol. Clin. Pharmacokinet. 11, 343-353 (1986).
23. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and C. Klenk: Measurement of protein using bicinchonic acid. Anal. Biochem. 150, 76-85 (1985).
24. C. Stubley and J. G. P. Stell: Investigation of the substrate-binding site of aldehyde oxidase. J. Pharm. Pharmacol. 32, 51P (1980).
25. W. W. Hall and T. A. Krenitsky: Aldehyde oxidase from rabbit liver: specificity toward purines and their analogs. Arch. Biochem. Biophys. 251, 36-46 (1986).
26. T. A. Krenitsky, T. Spector, and W. W. Hall: Xanthine oxidase from human liver: purification and characterization. Arch. Biochem. Biophys. 247, 108-119 (1986).
27. C. Beedham, S. E. Bruce, and D. J. Rance: Tissue distribution of the molybdenum hydroxylases, aldehyde oxidase and xanthine oxidase, in male and female guinea pigs. Eur. J. Drug Metab. Pharmacokin. 12, 303-306 (1987).
28. J. A. Duley, O. Harris, and R. S. Holmes: Analysis of human alcohol-metabolizing and aldehyde-metabolizing isozymes by electrophoresis and isoelectric focusing. Clin. Exp. Res. 9, 263-271 (1985).
29. D. G. Johns: Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J. Clin. Invest. 46, 1492-1505 (1967).
30. G. Panoutsopolous: Hepatic oxidation of aromatic aldehydes. Ph.D. Thesis, University of Bradford, UK (1994).
31. 1-methylnicotinamide and pyridoxal. Arch. Biochem. Biophys. 145, 27-34 (1971).
32. S. Gluecksohn-Waelsch, P. Greengard, G. P. Quinn, and L. S. Teicher: Genetic variations of an oxidase in mammals. J. Biol. Chem. 242, 1271-1273 (1967).
33. D. W. Lundgren, H. Tevesz, and E. A. Krill: Alternate putrescine metabolites: quantitative analysis of Δ'-pyrroline oxidation to 2-pyrrolidone in tissue homogenates by high pressure liquid chromatography. Anal. Biochem. 148, 461-470 (1985).
34. S. M. Taylor, C. Stubley-Beedham, and J. G. P. Stell: Simultaneous formation of 2-quinolones and 4-quinolones from quinolinium cations catalyzed by aldehyde oxidase. Biochem. J. 220, 67-74 (1984).
35. Y. Moriwaki, T. Yamamoto, Y. Nasako, S. Takahashi, M. Suda, K. Hiroishi, T. Hada, and K. Higashino: In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase. Biochem. Pharmacol. 46, 975-981 (1993).
36. S. Daniels and J. J. Schentag: Drug interaction studies and safety of famciclovir in healthy volunteers: a review. Antiviral Chem. Chemother. 4 Suppl 1, 57-64 (1993).
37. B. Kaye, J. L. Offerman, J. L. Reid, H. L. Elliott, and W. S. Willis: A species-differences in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14, 935-945 (1984).
38. B. Kaye, D. J. Rance, and L. Waring: Oxidative-metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15, 237-242 (1985).
39. C. Beedham: The role of non-P450 enzymes in drug oxidation. Pharm. World Sci., 19, 1-9 (1997).